Google NewsResMed Inc (ASX:RMD) Stock on Investors' Radar: Why Is the Share Price Moving? - Kalkine
ResMed Inc (ASX:RMD) Stock on Investors' Radar: Why Is the Share Price Moving? Kalkine
Resmed (RMD) News
Latest articles and price-sensitive announcements with AI sentiment classification.
KalkineWhat Does ResMed’s (ASX:RMD) Dividend Update Mean for CDI Holders?
Highlights ResMed (ASX:RMD) has updated its dividend notification for holders of CHESS Depositary Interests on the Australian Securities Exchange. The announcement clarifies the foreign exchange mechanism used to translate the distribution for Australian CDI holders. Cross-border withholding tax treatment remains an important consideration for eligible Australian investors receiving ResMed distributions. ResMed (ASX:RMD) has provided Australian investors with an updated dividend notification c...
ASX
Can ResMed (ASX:RMD) Reshape the Healthcare Outlook?
Highlights ResMed is being assessed through demand durability, product adoption and the quality of execution rather than short-term market direction. The healthcare stocks backdrop makes margin quality and research investment especially useful when separating company evidence from sector noise. Upcoming disclosures can clarify whether global execution is supporting or constraining the operating story around ResMed. Reporting-season volatility has sharpened the divide between narrative and exe...
ResMed (ASX:RMD): Why does All Ordinaries context matter?
Highlights For ResMed, the All Ordinaries backdrop is useful only as a comparison point; the stronger evidence comes from how research intensity feeds into market penetration. ResMed is approached from the quality of execution quality, not from a broad market-direction call. The analysis works backwards from market penetration to test what research intensity is actually saying about the business. That company-first framing keeps the All Ordinaries reference useful without allowing the index to ...
ResMed (ASX:RMD) Catalyst Watch: What Could Move Shares Next on 19 August
Highlights The 19 August reporting calendar includes ARB Corporation, Bega Cheese, Breville Group, BWP Trust and Deterra Royalties among companies scheduled to report. ResMed (ASX:RMD) is the primary company lens, while CSL (ASX:CSL), Cochlear (ASX:COH), Pro Medicus (ASX:PME) provide category context. The article focuses on earnings quality, product demand and healthcare growth durability without using directional investment recommendations. The central question for healthcare stocks is no lo...
Why Does ResMed (ASX:RMD) Matter Today?
Highlights ResMed remains closely watched as sleep and respiratory care devices, software and patient access shapes its place within Australia's healthcare stocks landscape. Operational delivery, capital discipline and clear disclosure remain central to how the company's progress is assessed. Broader demand linked to ageing populations, improved diagnosis and demand for effective treatment pathways continues influencing the sector conversation. Australia's sharemarket is moving through an act...
ResMed Lifts Dividend But Shares Slide On Caution (ASX:RMD)
Highlights ResMed delivered a solid full-year result with revenue in line with expectations and a lift to its dividend. Despite the steady numbers, shares slid sharply as the market focused on the coming year's forward outlook. Lingering competitive and weight-loss drug related questions continue to shape sentiment toward the sleep therapy leader. ResMed (ASX:RMD) delivered a full-year result broadly in line with expectations and lifted its dividend by a healthy margin, yet the stock slid sha...
ResMed (ASX:RMD) Steadies After Its Latest Update
Highlights Device and mask revenue growth outpaced the wider medical technology group this reporting stretch. Gross margin expansion came despite persistent freight and component cost pressure. Software and residential care services now form a distinct part of the revenue mix. ResMed (ASX:RMD), the dual-listed sleep and respiratory device manufacturer with its operational base in San Diego and a long-standing Australian listing, steadied through the past week after delivering a closing-period...
ResMed (ASX:RMD) Shares Going Ex-Dividend: What Income Investors Need to Know - Kalkine
ResMed (ASX:RMD) Shares Going Ex-Dividend: What Income Investors Need to Know Kalkine
What Is ResMed (ASX:RMD) Revealing About Healthcare?
Highlights ResMed is viewed through clinical demand, product adoption and service volumes, keeping the discussion anchored to company-specific operating evidence. The Healthcare Stocks lens is used only as context; the article separates ResMed's business model from broader sector shorthand. Fresh disclosures around regulatory pathway, capacity utilisation and international reach are the most useful checkpoints for judging how the narrative is evolving. For Australian shares, the more useful s...
Why ResMed (ASX:RMD) Could Be Worth Watching in Midcap Stocks Now?
Highlights Attention on ResMed is shifting from broad headlines toward the mechanics of the business. The current midcap stocks discussion includes market share, operating leverage and competitive positioning. A clearer market narrative depends on consistent evidence across demand, delivery and financial flexibility. Australian equities are moving through a period in which sector labels alone explain less than they once did. ResMed (ASX:RMD) is being viewed through a sharper operating lens, w...
ResMed Inc. (ASX:RMD): Why Is Value Back in Focus?
Highlights ResMed combines global sleep and breathing health demand with a recurring device, mask and digital-care ecosystem. Recent operating momentum has been supported by stronger demand, manufacturing efficiency and improved gross-margin performance. The valuation discussion increasingly centres on earnings durability, cash generation and whether operational progress can support a more balanced market assessment. Australian healthcare shares remain under close scrutiny as the market reass...
Motley FoolWhy ResMed shares are tumbling 6% today despite strong results
Here's what spooked investors. The post Why ResMed shares are tumbling 6% today despite strong results appeared first on The Motley Fool Australia.
ResMed posts strong Q4 earnings, lifts dividend
The sleep disorder treatment company had another record quarter. The post ResMed posts strong Q4 earnings, lifts dividend appeared first on The Motley Fool Australia.
Deferral of Conversions between Australian and US Registers
other announcement
Resmed Announces Results for the Fourth Quarter of FY2026
other announcement
ResMed (ASX:RMD) ClimbsHigher as Healthcare Stocks Advanced—What Matters for Long-Term Investors? - Kalkine
ResMed (ASX:RMD) ClimbsHigher as Healthcare Stocks Advanced—What Matters for Long-Term Investors? Kalkine
ResMed (ASX:RMD): Can Operating Delivery Change the Story?
Highlights ResMed enters the reporting period with device demand and gross margin central to the next company disclosure and the wider market debate. The Healthcare Stocks backdrop is testing volumes, reimbursement and operating margins as rates, demand and capital discipline shape market interpretation. A comparison with Fisher & Paykel Healthcare clarifies differences in scale, operating exposure, funding needs and sensitivity to external conditions. Local equities move into the current ...
What Makes ResMed (ASX:RMD) a Health Signal?
Highlights ResMed is drawing attention as sleep health strength helping the sector's rebound. Today's ASX tone is shaped by large healthcare names are regaining attention as rate fear cools. The key question is whether recurring device demand can offset broad sector nerves. A: ustralia's sharemarket has opened with a firmer pulse, and CSL (ASX:CSL), a global biotechnology company with blood products and vaccines exposure, is helping frame why ResMed matters to the latest conversation around h...
Down 31%: Is there any chance of a rebound from ResMed shares?
The ASX healthcare shares lost 31% over the past 12 months. The post Down 31%: Is there any chance of a rebound from ResMed shares? appeared first on The Motley Fool Australia.
ResMed (ASX:RMD) Dividend Outlook: What Income Investors Are Watching? - Kalkine
ResMed (ASX:RMD) Dividend Outlook: What Income Investors Are Watching? Kalkine
ResMed (ASX:RMD) Shares Slip as Healthcare Stocks Weaken Across the ASX - Kalkine
ResMed (ASX:RMD) Shares Slip as Healthcare Stocks Weaken Across the ASX Kalkine
ResMed Sharpens Focus With Software Arm Sale
Highlights A respiratory-care leader has agreed to offload a US healthcare software business at a healthy gain. The divestment lets the company lean harder into its core sleep and breathing franchise. The move underscores a broader push across medical-device names to streamline their portfolios. Portfolio housekeeping rarely grabs headlines, but a fresh divestment has put one of the market's most globally recognised device makers back in the conversation. ResMed (ASX:RMD), the sleep-apnoea an...
How Does ResMed (ASX:RMD) Anchor the Health Mid-Cap Revival?
Highlights A sleep and breathing device maker anchored a broader recovery in health mid caps. Steady demand for treatment of sleep apnoea underpins a resilient, recurring revenue base. The sector rebounded firmly after a bruising stretch earlier in the financial year. A recovery in Australian health stocks gathered pace this month, with a global sleep and breathing device maker anchoring the turn. ResMed (ASX:RMD), a medical technology company that designs devices and software to treat sleep ...
ASX health mid caps revive as ResMed (ASX:RMD) steadies
Highlights A sleep and breathing device maker anchored a broader recovery in health mid caps. Steady demand for treatment of sleep apnoea underpins a resilient, recurring revenue base. The sector rebounded firmly after a bruising stretch earlier in the financial year. A recovery in Australian health stocks gathered pace this month, with a global sleep and breathing device maker anchoring the turn. ResMed (ASX:RMD), a medical technology company that designs devices and software to treat sleep ap...
Why Is ResMed (ASX:RMD) Back in Healthcare Focus?
Highlights ResMed is drawing attention as demand for sleep and respiratory care devices becomes a key measure of healthcare resilience. Device volumes, recurring mask sales, margin discipline and cash generation remain central to the companys operating narrative. Connected health services add depth to the business, though patient access, competition and currency movements continue to shape the wider debate. The Australian share market is moving through a more selective phase as rate cauti...
How much could ResMed shares rise according to Morgans?
Current share price weakness could be an opportunity. The post How much could ResMed shares rise according to Morgans? appeared first on The Motley Fool Australia.
ResMed (ASX:RMD) Shares Slide as Healthcare Stocks Lose Ground - Kalkine
ResMed (ASX:RMD) Shares Slide as Healthcare Stocks Lose Ground Kalkine
What Puts ResMed (ASX:RMD) At The Heart Of Healthcare Reset?
Highlights ResMed is being reassessed through sleep-device demand, sharper portfolio focus and the impact of its software divestment. The healthcare sector is placing greater weight on core earnings quality, margin discipline and repeatable commercial delivery. Device competition, currency movements and capital allocation remain important tests as market expectations become more selective. Australias share market is moving through a demanding phase in which strong sector labels are no lon...
Top Healthcare Stocks: Is ResMed (ASX:RMD) Sharpening Its Focus?
Highlights ResMed is drawing attention as sleep-device demand keeps global respiratory healthcare firmly in the market conversation. Portfolio focus, connected software and disciplined cash conversion are becoming more important than broad healthcare enthusiasm. Market confidence increasingly depends on whether device strength and digital services support a coherent operating model. ResMed remains in focus as sleep-device demand, connected software, portfolio discipline, recurring patient...
ResMed (ASX:RMD) Falls Almost 5% as Healthcare Stocks Become One of the ASX's Biggest Drags - Kalkine
ResMed (ASX:RMD) Falls Almost 5% as Healthcare Stocks Become One of the ASX's Biggest Drags Kalkine
Why Is ResMed (ASX:RMD) Leading the Healthcare Stocks Recovery?
Highlights ResMed remains in focus as resilient medical device demand strengthens the healthcare sector narrative. Patient adherence, supply chain efficiency and connected care technologies continue shaping operational performance. Healthcare companies are increasingly being assessed through execution quality, financial discipline and sustainable demand. ResMed remains central to Australia's healthcare sector discussion as medical device dema...
Why Are ResMed (ASX:RMD) and TechnologyOne (ASX:TNE) Long-Term ASX Shares to Watch?
Highlights ResMed continues expanding its connected healthcare and sleep therapy business across global markets. TechnologyOne is strengthening its cloud software platform through long-term customer relationships and recurring revenue. Healthcare innovation and enterprise software remain important structural growth themes across the Australian market. ResMed Inc (ASX:RMD) and TechnologyOne Ltd (ASX:TNE) continue attracting attention as two established Australian compa...
What Makes ResMed (ASX:RMD) A Health Quality Check?
Highlights ResMed is being watched through sleep health demand as the ASX mood stays selective. Healthcare Stocks screens are shifting toward device demand and channel strength instead of broad market excitement. CSL and Pro Medicus add context for readers comparing medical devices exposure. The Australian share market has entered the new session with a familiar but sharper test: where is reliable evidence hiding when index direction is uneven? ResMed (ASX:RMD), sleep ...
ResMed (ASX:RMD) Trades Below Global MedTech Peers As Value Focus Returns
Highlights ResMed (ASX:RMD) has retreated despite continued operational momentum across its sleep and respiratory care business. The healthcare company is trading below valuation levels typically seen among global medical technology peers. Temple & Webster (ASX:TPW) also features among Australian companies attracting attention as a value-oriented growth story. ResMed Limited (ASX:RMD), the Australian-founded global medical technology company specialising in sleep ...
What Does ResMed's (ASX:RMD) MatrixCare Sale Mean for Its Future Growth Strategy?
Highlights ResMed has agreed to divest its MatrixCare business as part of its ongoing portfolio optimisation strategy. The company plans to use the proceeds to support share repurchases and broader corporate initiatives. The transaction strengthens ResMed's focus on its core sleep health, respiratory care and connected care businesses. ResMed Inc. (ASX:RMD) has announced the divestment of its MatrixCare business, marking another strategic step in refining its healthca...
ResMed's $490m MatrixCare sale: What it means
ResMed announces $490 million sale of MatrixCare and future shareholder returns. The post ResMed's $490m MatrixCare sale: What it means appeared first on The Motley Fool Australia.
Resmed Announces Agreement to Sell MatrixCare Business
other announcement
ResMed CDI (ASX:RMD) Shares Gain as Investors Watch Healthcare Equipment Trends - Kalkine
ResMed CDI (ASX:RMD) Shares Gain as Investors Watch Healthcare Equipment Trends Kalkine
Down 22%! 3 reasons to buy the big dip in ResMed shares today
Two leading analysts deliver their verdicts on ResMed’s beaten-down share price. The post Down 22%! 3 reasons to buy the big dip in ResMed shares today appeared first on The Motley Fool Australia.
Why Are ResMed (ASX:RMD) Shares in Focus as ASX Preview Signals a Mixed Monday?
Highlights Australian shares are set for a softer opening despite positive momentum across major European markets. Rising gold and firmer crude oil prices are placing resource and energy companies under renewed attention. Healthcare, shipbuilding and commodity-linked companies headline the market watchlist for the new trading week. Australian shares begin the week with mixed global signals as en...
Can ResMed (ASX:RMD) and Pro Medicus Lead the Next Growth Revival?
Highlights Healthcare is emerging as a key focus as quality businesses regain attention across the Australian share market. ResMed (ASX:RMD), Pro Medicus (ASX:PME), CSL (ASX:CSL) and Cochlear (ASX:COH) highlight how the market is rewarding stronger business fundamentals over broad sector enthusiasm. A more selective market backdrop is encouraging closer attention to cash generation, operational consistency and balance sheet strength. ...
ResMed Shares Close Higher, As RMD Added To Bullish Watch List - thebull.com.au
ResMed Shares Close Higher, As RMD Added To Bullish Watch List thebull.com.au
ResMed (ASX:RMD): Why Is Healthcare Software Standing Out?
Highlights Healthcare stocks are drawing fresh ASX attention as software-linked exposure adds a stronger quality lens. ResMed, Sonic Healthcare and Pro Medicus show different parts of the healthcare sector. Market focus is shifting toward execution, recurring demand and clearer business resilience. Healthcare stocks are gaining fresh ASX attention as ResMed, Sonic Healthcare, Pro Medicus, CS...
ResMed (ASX:RMD) Pushes Back Against GLP-One Market Fears
Highlights ResMed’s latest quarterly update challenges concerns that weight-loss medicines could weaken demand for sleep apnoea devices. Strong revenue momentum and improved margins have helped reshape the conversation around the healthcare company. The broader [ASX 200] healthcare landscape is watching whether sleep therapy demand remains resilient. ResMed has found itself at the centre of one of the biggest healthcare debates on ...
ResMed (ASX:RMD): Why Are Healthcare Stocks Under Watch?
Highlights ASX healthcare stocks are being judged through earnings proof, not headline momentum. Margin repair, clinical demand and reimbursement settings are shaping the sector debate. ResMed, Sonic Healthcare and Ramsay Health Care are framing the new financial year healthcare story. ASX healthcare stocks face a sharper new financial year test as margin repair, clinical demand and reimburs...
Why I think ResMed shares are a strong buy in July
I think alower share price has made this global healthcare business look more attractive to me for the long term. The post Why I think ResMed shares are a strong buy in July appeared first on The Motley Fool Australia.
Resmed to Report Fourth Quarter Fiscal 2026 Results
other announcement
Why Is ResMed (ASX:RMD) Winning Back the ASX 200 Healthcare Story?
Highlights ResMed has delivered solid quarterly growth as concerns surrounding GLP-one therapies ease. Revenue growth and stronger operating margins have reinforced confidence in the company's core business. Continued demand for sleep-related healthcare solutions has strengthened Australia's Healthcare Stocks sector. ResMed's latest quarterly performance hig...
Why ResMed (ASX:RMD) Is Rebuilding Confidence on the ASX 200?
Highlights ResMed remained operationally resilient despite broad healthcare sector weakness. Competitive concerns surrounding weight-loss therapies have eased as demand stays stable. The global medical technology leader continues attracting attention across Healthcare Stocks . ResMed continues demonstrating resilient healthcare demand through respiratory dev...
ResMed (ASX:RMD) Stock Moves Higher — What Investors Should Know? - Kalkine
ResMed (ASX:RMD) Stock Moves Higher — What Investors Should Know? Kalkine